Boston Scientific (Natick, Massachusetts) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is a transcatheter aortic valve replacement (TAVR) device that is both fully repositionable and retrievable prior to release. Read More
